Babl evaluated the prospect of immune checkpoint blockade with single-agent MCT4 inhibition and combined MCT4 and MCT1 inhibition in colorectal carcinoma (CRC) [164]. The gene discussed is SLC16A1; the disease is colorectal carcinoma.